苯溴马隆与非布司他在治疗2型糖尿病伴高尿酸血症的获益及安全性  

Benefit and safety of benzbromarone and febuxostat in the treatment of type 2 diabetes with hyperuricemia

作　　者：商雪莹[1] 邓霖[1] 宋雨凌[1] 韩玲玲[1] 

机构地区：[1]中国医科大学附属第四医院内分泌科,沈阳110032

出　　处：《实用药物与临床》2017年第4期402-405,共4页Practical Pharmacy and Clinical Remedies

摘　　要：目的评价苯溴马隆与非布司他在治疗2型糖尿病伴高尿酸血症的获益及安全性。方法将85例已确诊的2型糖尿病伴尿酸升高的患者随机分为苯溴马隆组(A组,44例)和非布司他组(B组,41例)。两组均给予饮食控制、口服降糖药和(或)胰岛素治疗,A组给予苯溴马隆50 mg/d口服,B组给予非布司他40 mg/d口服,疗程为3个月。结果与苯溴马隆比较,非布司他能够更快、更有效地降低血尿酸水平(P<0.05),但最终达标率比较差异无统计学意义(P>0.05)。两组均出现不同程度的不良反应,B组痛风发作率较高,而A组发生其他不良反应较多。治疗后两组患者Hb A1c均改善(P<0.05),两组比较差异无统计学意义(P>0.05)。治疗前、后两组空腹C肽水平比较差异无统计学意义(P>0.05)。治疗3个月后,A组患者120分C肽水平得到改善(P<0.05),但非布司他组未见明显改善(P>0.05)。结论在2型糖尿病合并高尿酸血症的患者中,应用非布司他及苯溴马隆治疗均能有效降低血尿酸水平,改善患者血糖。苯溴马隆能改善餐后C肽水平。Objective To evaluate the benefit and safety of benzbromarone and febuxostat in the treatment of type 2 diabetes with hyperuricemia. Methods Totally 85 patients who had been diagnosed with type 2 diabetes with hyperuricemia were divided into benzbromarone group （ group A, n = 44 ） and febuxostat group （ group B, n = 41 ）. Both groups received diet control, oral hypoglycemic agents and （or） insulin therapy. Patients in group A took benzbro- marone （50 mg/d） orally, and the patients in group B took febuxostat （40 mg/d） orally for 3 months. Results Com- pared with benzbromarone, febuxosta could reduce the uric acid levels more quickly and effectively （ P 〈 0. 05 ） , but there was no significant difference in the eventual success rates between the two groups （ P 〉 0. 05 ）. Both groups had adverse reactions, group B had higher rate of gout, while group A had higher rate of other adverse reactions. After treat- ments ,the HbAlc in both groups was improved （ P 〈 0, 05 ） , and there was no significant difference between the two groups （ P 〉 0. 05 ）. There was no significant difference in fasting C-peptide levels between the two groups before and after treatment （ P 〉 0. 05 ）. The 120-min C-peptide levels was improved in group A at 3 months after treatment （ P 〈 0. 05 ） ,but there was no significant difference in group B （ P 〉 0. 05 ）. Conclusion Both febuxostat and benzbromarone can effectively reduce the blood uric acid level of the patients of type 2 diabetes with hyperuricemia, and improve the blood glucose level. Benzbromarone can improve the postprandial C-peptide levels.

关 键 词：苯溴马隆 非布司他 2型糖尿病 高尿酸血症 

分 类 号：R589.7[医药卫生—内分泌] R587.1[医药卫生—内科学]